Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Other Non Operating Income (2019 - 2026)

ADC Therapeutics has reported Other Non Operating Income over the past 7 years, most recently at $2.6 million for Q1 2026.

  • Quarterly results put Other Non Operating Income at $2.6 million for Q1 2026, up 1196.55% from a year ago — trailing twelve months through Mar 2026 was $3.6 million (up 80.16% YoY), and the annual figure for FY2022 was -$604.0 million, changed.
  • Other Non Operating Income reached $2.6 million in Q1 2026 per ADCT's latest filing, up from $925000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $274.0 million in Q1 2023 and bottomed at -$5.1 million in Q2 2023.
  • Median Other Non Operating Income over the past 4 years was $892500.0 (2023), compared with a mean of $27.5 million.
  • The largest annual shift saw Other Non Operating Income tumbled 106.61% in 2025 before it soared 1196.55% in 2026.
  • Over 4 years, Other Non Operating Income stood at $860000.0 in 2023, then surged by 88.84% to $1.6 million in 2024, then plummeted by 43.04% to $925000.0 in 2025, then surged by 184.54% to $2.6 million in 2026.
  • Business Quant data shows Other Non Operating Income for ADCT at $2.6 million in Q1 2026, $925000.0 in Q3 2025, and -$182000.0 in Q2 2025.